We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

NeoGenomics Inc (NEO) NPV

Sell:$13.80 Buy:$14.66 Change: $0.74 (5.51%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$13.80
Buy:$14.66
Change: $0.74 (5.51%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$13.80
Buy:$14.66
Change: $0.74 (5.51%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

Contact details

Address:
9490 Neogenomics Way
FORT MYERS
33912
United States
Telephone:
+1 (239) 7680600
Website:
https://neogenomics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NEO
ISIN:
US64049M2098
Market cap:
$1.71 billion
Shares in issue:
127.67 million
Sector:
Health Care Services
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Christopher Smith
    Chief Executive Officer, Director
  • Jeffrey Sherman
    Chief Financial Officer
  • Vishal Sikri
    President - Advanced Diagnostics
  • Melody Harris
    Chief Operating Officer, President - Informatics
  • Shashikant Kulkarni
    Executive Vice President of Research and Development, Chief Scientific Officer
  • Marcus Silva
    Senior Vice President, General Manager - Oncology Diagnostics
  • Cynthia Dieter
    Chief Accounting Officer, Controller
  • Alicia Olivo
    General Counsel, Company Secretary
  • Warren Stone
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.